These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
113 related articles for article (PubMed ID: 9446947)
1. Combined radiochemotherapy for organ preservation in head and neck cancer: review of literature and personal experience. Marmiroli L; Ausili-Cèfaro G; Nardone L; Fiorentino G; Genovesi D; Salvi G Rays; 1997; 22(3):425-40. PubMed ID: 9446947 [TBL] [Abstract][Full Text] [Related]
2. Intensive chemoradiotherapy as a primary treatment for organ preservation in patients with advanced cancer of the head and neck: efficacy, toxic effects, and limitations. Hanna E; Alexiou M; Morgan J; Badley J; Maddox AM; Penagaricano J; Fan CY; Breau R; Suen J Arch Otolaryngol Head Neck Surg; 2004 Jul; 130(7):861-7. PubMed ID: 15262764 [TBL] [Abstract][Full Text] [Related]
3. Preoperative paclitaxel, carboplatin, and radiation therapy in advanced head and neck cancer (stage III and IV). Wanebo HJ; Chougule P; Ready N; Koness RJ; Akerley W; McRae R; Nigri P; Leone L; Webber B; Safran H Semin Radiat Oncol; 1999 Apr; 9(2 Suppl 1):77-84. PubMed ID: 10210544 [TBL] [Abstract][Full Text] [Related]
4. Induction paclitaxel and carboplatin for patients with head and neck carcinoma. Analysis of 62 patients treated between 1994 an 1999. Dunphy FR; Dunleavy TL; Harrison BR; Trinkaus KM; Kim HJ; Stack BC; Needles B; Boyd JH Cancer; 2001 Mar; 91(5):940-8. PubMed ID: 11251945 [TBL] [Abstract][Full Text] [Related]
5. Cisplatin, fluorouracil, and leucovorin induction chemotherapy followed by concurrent cisplatin chemoradiotherapy for organ preservation and cure in patients with advanced head and neck cancer: long-term follow-up. Psyrri A; Kwong M; DiStasio S; Lekakis L; Kassar M; Sasaki C; Wilson LD; Haffty BG; Son YH; Ross DA; Weinberger PM; Chung GG; Zelterman D; Burtness BA; Cooper DL J Clin Oncol; 2004 Aug; 22(15):3061-9. PubMed ID: 15284256 [TBL] [Abstract][Full Text] [Related]
6. Carboplatin and radiotherapy in the treatment of head and neck cancer: six years' experience. Zamboglou N; Schnabel T; Kolotas C; Achterrath W; Strehl H; Dalhäuser S; Vogt HG; Lenaz L; Schmitt G Semin Oncol; 1994 Oct; 21(5 Suppl 12):45-53. PubMed ID: 7992066 [TBL] [Abstract][Full Text] [Related]
7. Can concomitant-boost accelerated radiotherapy be adopted as routine treatment for head-and-neck cancers? A 10-year single-institution experience. Allal AS; Taussky D; Mach N; Becker M; Bieri S; Dulguerov P Int J Radiat Oncol Biol Phys; 2004 Apr; 58(5):1431-6. PubMed ID: 15050320 [TBL] [Abstract][Full Text] [Related]
8. Induction chemotherapy followed by concomitant chemoradiation therapy in advanced head and neck cancer: a phase II study for organ-sparing purposes evaluating feasibility, effectiveness and toxicity. Mantovani G; Proto E; Massa E; Mulas C; Madeddu C; Mura L; Mudu MC; Astara G; Murgia V; Gramignano G; Ferreli L; Camboni P; Lusso MR; Mocci M; Tore G; Mura M; Amichetti M; Maccio A Int J Oncol; 2002 Feb; 20(2):419-27. PubMed ID: 11788911 [TBL] [Abstract][Full Text] [Related]
9. The evaluation of amifostine for mucosal protection in patients with advanced loco-regional squamous cell carcinomas of the head and neck (SCCHN) treated with concurrent weekly carboplatin, paclitaxel, and daily radiotherapy (RT). Suntharalingam M; Jaboin J; Taylor R; Wolf J; Banglore M; Van Echo D; Ord R Semin Oncol; 2004 Dec; 31(6 Suppl 18):2-7. PubMed ID: 15726515 [TBL] [Abstract][Full Text] [Related]
10. Does induction chemotherapy still have a role in larynx preservation strategies? The experience of Institut Catala d'Oncologia in stage III larynx carcinoma. Majem M; Mesia R; Mañós M; Gomez J; Galiana R; Cardenal F; Juan A; Montes A; Perez FJ; Nogues J; Llluch JR Laryngoscope; 2006 Sep; 116(9):1651-6. PubMed ID: 16954998 [TBL] [Abstract][Full Text] [Related]
11. Split course hyperfractionated accelerated radio-chemotherapy (SCHARC) for patients with advanced head and neck cancer: influence of protocol deviations and hemoglobin on overall survival, a retrospective analysis. Stadler P; Putnik K; Kreimeyer T; Sprague LD; Koelbl O; Schäfer C BMC Cancer; 2006 Dec; 6():279. PubMed ID: 17150114 [TBL] [Abstract][Full Text] [Related]
12. Intensity-modulated radiation treatment for head-and-neck squamous cell carcinoma--the University of Iowa experience. Yao M; Dornfeld KJ; Buatti JM; Skwarchuk M; Tan H; Nguyen T; Wacha J; Bayouth JE; Funk GF; Smith RB; Graham SM; Chang K; Hoffman HT Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):410-21. PubMed ID: 16168834 [TBL] [Abstract][Full Text] [Related]
13. Induction chemotherapy followed by concomitant TFHX chemoradiotherapy with reduced dose radiation in advanced head and neck cancer. Haraf DJ; Rosen FR; Stenson K; Argiris A; Mittal BB; Witt ME; Brockstein BE; List MA; Portugal L; Pelzer H; Weichselbaum RR; Vokes EE Clin Cancer Res; 2003 Dec; 9(16 Pt 1):5936-43. PubMed ID: 14676118 [TBL] [Abstract][Full Text] [Related]
14. Aggressive simultaneous radiochemotherapy with cisplatin and paclitaxel in combination with accelerated hyperfractionated radiotherapy in locally advanced head and neck tumors. Results of a phase I-II trial. Kuhnt T; Becker A; Pigorsch S; Pelz T; Bloching M; Passmann M; Lotterer E; Hänsgen G; Dunst J Strahlenther Onkol; 2003 Oct; 179(10):673-81. PubMed ID: 14566475 [TBL] [Abstract][Full Text] [Related]
15. Induction chemotherapy with cisplatin and 5-fluorouracil followed by chemoradiotherapy or radiotherapy alone in the treatment of locoregionally advanced resectable cancers of the larynx and hypopharynx: results of single-center study of 45 patients. Altundag O; Gullu I; Altundag K; Yalcin S; Ozyar E; Cengiz M; Akyol F; Yucel T; Hosal S; Sozeri B Head Neck; 2005 Jan; 27(1):15-21. PubMed ID: 15515158 [TBL] [Abstract][Full Text] [Related]
16. Pilot study of postoperative reirradiation, chemotherapy, and amifostine after surgical salvage for recurrent head-and-neck cancer. Machtay M; Rosenthal DI; Chalian AA; Lustig R; Hershock D; Miller L; Weinstein GS; Weber RS Int J Radiat Oncol Biol Phys; 2004 May; 59(1):72-7. PubMed ID: 15093901 [TBL] [Abstract][Full Text] [Related]
17. Voice and swallowing outcomes of an organ-preservation trial for advanced laryngeal cancer. Fung K; Lyden TH; Lee J; Urba SG; Worden F; Eisbruch A; Tsien C; Bradford CR; Chepeha DB; Hogikyan ND; Prince ME; Teknos TN; Wolf GT Int J Radiat Oncol Biol Phys; 2005 Dec; 63(5):1395-9. PubMed ID: 16087298 [TBL] [Abstract][Full Text] [Related]
18. Necessity for adjuvant neck dissection in setting of concurrent chemoradiation for advanced head-and-neck cancer. Brizel DM; Prosnitz RG; Hunter S; Fisher SR; Clough RL; Downey MA; Scher RL Int J Radiat Oncol Biol Phys; 2004 Apr; 58(5):1418-23. PubMed ID: 15050318 [TBL] [Abstract][Full Text] [Related]
19. Randomized phase 2 study of concomitant chemoradiotherapy using weekly carboplatin/paclitaxel with or without daily subcutaneous amifostine in patients with locally advanced head and neck cancer. Haddad R; Sonis S; Posner M; Wirth L; Costello R; Braschayko P; Allen A; Mahadevan A; Flynn J; Burke E; Li Y; Tishler RB Cancer; 2009 Oct; 115(19):4514-23. PubMed ID: 19634161 [TBL] [Abstract][Full Text] [Related]
20. [Induction chemotherapy and larynx preservation: is such practice useful?]. Sarini J; Bocciolini C; Fournier C; Penel N; Kara A; Van JT; Lefebvre JL Bull Cancer; 2002 Apr; 89(4):411-7. PubMed ID: 12016041 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]